Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation

Blood

Volumn 117, Issue 15, 2011, Pages 4134-4141

  MacQuarrie, Jessica L ^a   Stafford, Alan R ^b   Yau, Jonathan W ^b   Leslie, Beverly A ^b   Vu, Trang T ^b   Fredenburgh, James C ^b   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

EID: 79954617276     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-290551     Document Type: Article

References (43)

1. Saito H. Contact factors in health and disease. Semin Thromb Hemost. 1987;13(1):36-49. (Pubitemid 17034602)
2. Salomon O, Seligsohn U. New observations on factor XI deficiency. Haemophilia. 2004;10(suppl 4):184-187. (Pubitemid 40045441)
3. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513-518.
4. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281. (Pubitemid 41043823)
5. Shariat-Madar Z, Mahdi F, Warnock M, et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood. 2006;108(1):192-199. (Pubitemid 43990628)
6. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281. (Pubitemid 351213410)
7. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19):3981- 3989.
8. Renne T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis. 2006;36(2):148-151.
9. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Nat Acad Sci U S A. 2006;103(4):903-908. (Pubitemid 43212194)
10. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Nat Acad Sci U S A. 2007;104(15):6388-6393. (Pubitemid 47186104)
11. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol. 2005;83(2):106-118. (Pubitemid 40469318)
12. Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood. 1983;62(5):1016-1021. (Pubitemid 14237323)
13. Jones AL, Hulett MD, Altin JG, Hogg P, Parish CR. Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem. 2004;279(37):38267-38276. (Pubitemid 39295974)
14. Tsuchida-Straeten N, Ensslen S, Schafer C, et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost. 2005;3(5):865-872. (Pubitemid 41632812)
15. Vestergaard AB, Andersen HF, Magnusson S, Halkier T. Histidine-rich glycoprotein inhibits contact activation of blood coagulation. Thromb Res. 1990;60(5):385-396.
16. Shigekiyo T, Ohshima T, Oka H, Tomonari A, Azuma H, Saito S. Congenital histidine-rich glycoprotein deficiency. Thromb Haemost. 1993;70(2):263-265. (Pubitemid 23222481)
17. Borza DB, Morgan WT. Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J Biol Chem. 1997;272(9):5718-5726. (Pubitemid 27102400)
18. Juarez JC, Guan X, Shipulina NV, et al. Histidineproline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 2002;62(18):5344-5350. (Pubitemid 35024611)
19. Borza DB, Shipulina NV, Morgan WT. Effects of histidine-proline-rich glycoprotein on plasminogen activation in solution and on surfaces. Blood Coag Fibrinolysis. 2004;15(8):663-672. (Pubitemid 39612972)
20. Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry. 1979;18(20):4419-4425.
21. Foote JW, Delves HT. Albumin bound and alpha 2-macroglobulin bound zinc concentrations in the sera of healthy adults. J Clin Pathol. 1984;37(9):1050-1054. (Pubitemid 14072288)
22. Poon IK, Patel KK, Davis DS, Parish CR, Hulett MD. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood. 2011;117(7):2093-2101.
23. Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation? Thromb Haemost. 2008;99(3):457-460. (Pubitemid 351549278)
24. Colman RW. Are hemostasis and thrombosis two sides of the same coin? J Exp Med. 2006;203(3):493-495.
25. Lin J, Deng H, Jin L, et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem. 2006;49(26):7781-7791. (Pubitemid 46039665)
26. Borza DB, Tatum FM, Morgan WT. Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry. 1996;35(6):1925-1934.
27. Borza DB, Morgan WT. Histidine-proline-rich glycoprotein as a plasma pH sensor: modulation of its interaction with glycosaminoglycans by pH and metals. J Biol Chem. 1998;273(10):5493-5499. (Pubitemid 28124013)
28. Vanwildemeersch M, Olsson AK, Gottfridsson E, Claesson-Welsh L, Lindahl U, Spillmann D. The anti-angiogenic His/Pro-rich fragment of histidinerich glycoprotein binds to endothelial cell heparan sulfate in aZn2+-dependent manner. J Biol Chem. 2006;281(15):10298-10304. (Pubitemid 43864568)
29. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation. J Biol Chem. 2004;279(29):30114-30122. (Pubitemid 38937934)
30. Bernardo MM, Day DE, Halvorson HR, Olson ST, Shore JD. Surface-independent acceleration of factor XII activation by zinc ions: II. Direct binding and fluorescence studies. J Biol Chem. 1993;268(17):12477-12483. (Pubitemid 23182404)
31. Schousboe I. Endothelial cells express a matrix protein which binds activated factor XII in a zincindependent manner. Thromb Haemost. 2006;95(2):312-319.
32. Ravon DM, Citarella F, Lubbers YTP, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood. 1995;86(11):4134-4143.
33. Wagenaar-Bos IG, Hack CE. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am. 2006;26(4):615-632. (Pubitemid 44755113)
34. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 1985;260(3):1723-1729. (Pubitemid 15145450)
35. Shore JD, Day DE, Bock PE, Olson ST. Acceleration of surface-dependent autocatalytic activation of blood coagulation factor XII by divalent metal ions. Biochemistry. 1987;26(8):2250-2258. (Pubitemid 17080968)
36. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood. 2002;99(10):3585-3596. (Pubitemid 34534527)
37. Rojkjaer R, Schousboe I. The surface-dependent autoactivation mechanism of factor XII. Eur J Biochem. 1997;243(1):160-166. (Pubitemid 27060398)
38. Shigekiyo T, Yoshida H, Kanagawa Y, et al. Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular characterization. Thromb Haemost. 2000;84(4):675-679.
39. Houlihan LM, Davies G, Tenesa A, et al. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet. 2010;86(4):626-631.
40. Saigo K, Yoshida A, Ryo R, Yamaguchi N, Leung LL. Histidine-rich glycoprotein as a negative acute phase reactant. Am J Hematol. 1990;34(2):149-150. (Pubitemid 20180108)
41. Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest. 1986;77(4):1305-1311. (Pubitemid 16047154)
42. Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry. 1986;25(8):2220-2225. (Pubitemid 16036040)
43. Lee C, Bongcam-Rudloff E, Sollner C, Jahnen-Dechent W, Claesson WL. Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front Biosci. 2009;14:2911-2922.